Just a few neoantigens may be enough for T cells to control prostate cancer
In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
Frontiers Resistance Mechanisms of Anti-PD1/PDL1 Therapy in
Immunotherapy: Constructive Approach for Breast Cancer
Pharmaceutics, Free Full-Text
Cancer vaccines are showing promise. Here's how they work.
Neoantigens: promising targets for cancer therapy
Photodynamic therapy combined with immunotherapy: Recent advances
Nanomedicine for advanced cancer immunotherapy - ScienceDirect
Harnessing the potential of CAR-T cell therapy: progress
A primer on recent developments in cancer immunotherapy, with a
Neoantigens: promising targets for cancer therapy
After Covid-19, can mRNA vaccines help with cancer as well?
IJMS, Free Full-Text
Will cancer vaccines change the way we treat cancer?
